Navigation
Recherche
|
Cancer-Fighting Immune Cells Could Soon Be Engineered Inside Our Bodies
mardi 27 mai 2025, 18:00 , par Slashdot
![]() Current CAR-T treatments require removing a patient's T cells, shipping them to specialized facilities for genetic engineering, then returning them weeks later at costs around $500,000 per dose. The new 'in vivo' approaches use viral vectors or RNA-loaded nanoparticles to deliver genetic instructions directly to T cells circulating in the bloodstream, which could reduce costs by an order of magnitude. Companies including Capstan Therapeutics, co-founded by Nobel laureates, and AstraZeneca-backed EsoBiotec have launched early human trials. While only about 200 US centers currently offer traditional CAR-T therapy, the approach could make the powerful treatment available on demand like conventional drugs. Read more of this story at Slashdot.
https://science.slashdot.org/story/25/05/27/1532255/cancer-fighting-immune-cells-could-soon-be-engin...
Voir aussi |
56 sources (32 en français)
Date Actuelle
mar. 3 juin - 00:15 CEST
|